News Releases

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 4, 2026
PDF Version
Read More
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
PDF Version
Read More
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
PDF Version
Read More
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
PDF Version
Read More
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2026
PDF Version
Read More
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
PDF Version
Read More